Page 459 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C4.1. Descriptive characteristics of the randomized controlled trials and comparative cohort studies considered
relevant to KQ4 (continued)
Author, Year Study name Comparison Study Sample Inclusion criteria Population description: Quality
[Pubmed ID] /Database duration size (total) Age Comments
PSA (ng/mL)
Study design Tumor grade
Stage
Randomized
study –
treatment
costs
Andersson 237 SPCG-4 WW vs. RP Median 212 <75 yr, life expectancy >10 yr, Age: WW, 64.4 yr; RP, 64.7 yr B
2011 followup T0d-T2 disease, WHO
21265595 11.8 yr for well/moderately differentiated, PSA: WW, <4, 27.6%; 4-6.9,
the WW PSA <50 ng/ml, no evidence of 13.3%; 7-10, 16.2%; 10.1-20,
Substudy of and 12.2 skeletal metastases on bone 27.6%; >20, 12.4%; unknown,
RCT yr for the scan; patients from the trial were 2.9%. RP, <4, 16.8%; 4-6.9,
RP included if they resided in the 15%; 7-10, 19.6%; 10.1-20,
counties where the two centers 29.9%; >20, 15.9%; unknown,
that randomized most patients 2.8%.
were located (Örebro and
Uppsala) Gleason score: WW, 2-4,
21.9%; 5-6, 48.6%; 7, 24.8%;
8-10, 2.9%; unknown, 1.9%.
RP, 2-4, 20.6%; 5-6, 49.5%; 7,
23.4%; 8-10, 2.8%; unknown,
3.7%.

Stage: WW: T1b,12.4%; T1c,
7.6%; T2, 80.0%; unknown,
0%. RP: T1b,10.3%; T1c, 8.4%;
T2, 81.3%; unknown, 0%.

C-147